These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

188 related items for PubMed ID: 6937988

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Magnesium metabolism. Studies in health, primary hyperparathyroidism and renal stone disease.
    Johansson G.
    Scand J Urol Nephrol Suppl; 1979; (51):1-48. PubMed ID: 293016
    [No Abstract] [Full Text] [Related]

  • 3. Magnesium metabolism in renal stone disease.
    Johansson G, Backman U, Danielson BG, Ljunghall S, Wikström B.
    Invest Urol; 1980 Sep; 18(2):93-6. PubMed ID: 7410037
    [Abstract] [Full Text] [Related]

  • 4. Biochemical and clinical effects of the prophylactic treatment of renal calcium stones with magnesium hydroxide.
    Johansson G, Backman U, Danielson BG, Fellström B, Ljunghall S, Wikström B.
    J Urol; 1980 Dec; 124(6):770-4. PubMed ID: 7441826
    [Abstract] [Full Text] [Related]

  • 5. Effects of magnesium hydroxide in renal stone disease.
    Johansson G, Backman U, Danielson BG, Fellström B, Ljunghall S, Wikström B.
    J Am Coll Nutr; 1982 Dec; 1(2):179-85. PubMed ID: 6764473
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Biochemical studies in calcium oxalate stone formers, with special reference to the effects of thiazide treatment.
    Ahlstrand C.
    Scand J Urol Nephrol Suppl; 1984 Dec; 81():1-93. PubMed ID: 6387895
    [No Abstract] [Full Text] [Related]

  • 9. Chlorthalidone reduces calcium oxalate calculous recurrence but magnesium hydroxide does not.
    Ettinger B, Citron JT, Livermore B, Dolman LI.
    J Urol; 1988 Apr; 139(4):679-84. PubMed ID: 3280829
    [Abstract] [Full Text] [Related]

  • 10. [The interrelationship between calcium and magnesium homeostasis and its significance for the relapse-prevention treatment of calcium nephrolithiasis].
    Tsachev K, Ivanov I.
    Vutr Boles; 1990 Apr; 29(4):48-52. PubMed ID: 2281659
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. The effects of potassium and magnesium supplementations on urinary risk factors of renal stone patients.
    Jaipakdee S, Prasongwatana V, Premgamone A, Reungjui S, Tosukhowong P, Tungsanga K, Suwantrai S, Noppawinyoowong C, Maskasame S, Sriboonlue P.
    J Med Assoc Thai; 2004 Mar; 87(3):255-63. PubMed ID: 15117041
    [Abstract] [Full Text] [Related]

  • 13. Metabolic study of hyperparathyroid and other renal stone formers using a very low intake of calcium and magnesium.
    Keynes WM, Barnes BA, Gordon E, Cope O.
    Br J Surg; 1969 Aug; 56(8):624. PubMed ID: 5797755
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Evaluation and medical management of the patient with calcium stone disease.
    Menon M, Krishnan CS.
    Urol Clin North Am; 1983 Nov; 10(4):595-615. PubMed ID: 6636376
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. [Urinary magnesium and its relationship to calcium in recurrent stone-formers and controls (author's transl)].
    Leskovar P, Hartung R, Siebert A, Wellnhofer E.
    Urologe A; 1980 Jul; 19(4):214-9. PubMed ID: 7414766
    [Abstract] [Full Text] [Related]

  • 19. [Effect of verapamil on urinary calcium and oxalate excretion in renal stone formers].
    Iguchi M, Ikegami M, Kiwamoto H, Umekawa T, Ishikawa Y, Kohri K, Kurita T.
    Hinyokika Kiyo; 1993 May; 39(5):425-31. PubMed ID: 8322624
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.